{
    "clinical_study": {
        "@rank": "119158", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Paclitaxel + BMS-906024", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024", 
                "arm_group_type": "Experimental", 
                "description": "5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Arm C: Carboplatin/Paclitaxel + BMS-906024", 
                "arm_group_type": "Experimental", 
                "description": "Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Arm D: Paclitaxel + BMS-906024", 
                "arm_group_type": "Experimental", 
                "description": "Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity"
            }, 
            {
                "arm_group_label": "Arm F: Carboplatin/Paclitaxcel and BMS-906024", 
                "arm_group_type": "Experimental", 
                "description": "Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in\n      combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus\n      Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic\n      solid tumors"
        }, 
        "brief_title": "Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "detailed_description": {
            "textblock": "DLTs = dose-limiting toxicities\n\n      MTD = Maximum tolerated dose"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com.\n\n        Inclusion Criteria:\n\n          -  Subjects with advanced or metastatic solid tumors  for whom a chemotherapy regimen is\n             considered appropriate\n\n          -  Subjects with non-small cell lung cancer and triple-negative breast cancer are\n             preferred\n\n          -  Biopsy accessible tumor (may use archived tumor samples under certain circumstances)\n\n          -  Life expectancy of at least 3 months\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n\n          -  Measurable disease\n\n        Exclusion Criteria:\n\n          -  Uncontrolled brain metastases\n\n          -  Infection\n\n          -  Gastrointestinal (GI) disease with increased risk of diarrhea (e.g. inflammatory\n             bowel disease)\n\n          -  Uncontrolled or significant cardiovascular disease\n\n          -  Subjects taking medications known to increase risk of Torsades de Pointes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653470", 
            "org_study_id": "CA216-003", 
            "secondary_id": "2012-003232-23"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: Paclitaxel + BMS-906024", 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }, 
            {
                "arm_group_label": "Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024", 
                "intervention_name": "5-Fluorouracil (5FU)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Adrucil", 
                    "Carac", 
                    "Efudix", 
                    "Efudex", 
                    "Fluoroplex"
                ]
            }, 
            {
                "arm_group_label": [
                    "Arm C: Carboplatin/Paclitaxel + BMS-906024", 
                    "Arm F: Carboplatin/Paclitaxcel and BMS-906024"
                ], 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "Paraplatin"
            }, 
            {
                "arm_group_label": "Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024", 
                "intervention_name": "Leucovorin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug", 
                "other_name": "Camptosar"
            }, 
            {
                "arm_group_label": [
                    "Arm C: Carboplatin/Paclitaxel + BMS-906024", 
                    "Arm D: Paclitaxel + BMS-906024", 
                    "Arm F: Carboplatin/Paclitaxcel and BMS-906024"
                ], 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }, 
            {
                "arm_group_label": [
                    "Arm A: Paclitaxel + BMS-906024", 
                    "Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024", 
                    "Arm C: Carboplatin/Paclitaxel + BMS-906024", 
                    "Arm D: Paclitaxel + BMS-906024", 
                    "Arm F: Carboplatin/Paclitaxcel and BMS-906024"
                ], 
                "intervention_name": "BMS-906024", 
                "intervention_type": "Drug", 
                "other_name": "Notch inhibitor"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Irinotecan", 
                "Carboplatin", 
                "Paclitaxel", 
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 23, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Anthony El-Khoueiry, Site 001"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Usc/Norris Comprehensive Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Site 0005"
                }, 
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Local Institution"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Siu-Chung Chu, Site 0003", 
                    "phone": "780-577-8137"
                }, 
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 1Z2"
                    }, 
                    "name": "Cross Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lillian L Siu, Site 0002", 
                    "phone": "416-946-4501", 
                    "phone_ext": "3450"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Glenwood Goss, Site 0004", 
                    "phone": "613-737-7700", 
                    "phone_ext": "70300"
                }, 
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "K1H 8L6"
                    }, 
                    "name": "The Ottawa Hospital Cancer Centre"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "Hungary: National Institute of Pharmacy"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety assessment based on reports of adverse events and clinical laboratory tests as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days after the last dose of study medication"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653470"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks", 
                "measure": "Maximum observed plasma concentration (Cmax) of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024), Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin", 
                "safety_issue": "No", 
                "time_frame": "16 time points up to first 3 cycles"
            }, 
            {
                "description": "Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks", 
                "measure": "Trough observed plasma concentration (Cmin) of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024), Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin", 
                "safety_issue": "No", 
                "time_frame": "16 time points up to first 3 cycles"
            }, 
            {
                "description": "Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks", 
                "measure": "Time of maximum observed plasma concentration (Tmax) of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024), Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin", 
                "safety_issue": "No", 
                "time_frame": "16 time points up to first 3 cycles"
            }, 
            {
                "description": "Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks", 
                "measure": "Area under the concentration-time curve during a dosing interval of tau [AUC(TAU)] of BMS-906024 and BMS-911557 (the active metabolite of BMS-906024)", 
                "safety_issue": "No", 
                "time_frame": "16 time points up to first 3 cycles"
            }, 
            {
                "description": "Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks", 
                "measure": "Area under the concentration-time curve from time 0 to the time of the last sample collected in the dosing interval [AUC(0-T)] of Paclitaxel, Irinotecan, SN-38 (the active metabolite of Irinotecan) and Carboplatin", 
                "safety_issue": "No", 
                "time_frame": "16 time points up to first 3 cycles"
            }, 
            {
                "description": "Duration of first 3 cycles for Arm A: 10 weeks; Arm B: 6 weeks; Arm C: 9 weeks", 
                "measure": "Steady-state infusion concentration (Css) of 5-Fluorouracil (5-FU)", 
                "safety_issue": "No", 
                "time_frame": "16 time points up to first 3 cycles"
            }, 
            {
                "measure": "Tumor response [as defined by Response Evaluation Criteria in Solid Tumors (RECIST) (v.1.1) criteria], best overall response (BOR), duration of response, and progression free survival (PFS) will be assessed", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks until confirmed disease progression, death or discontinuation for other reasons (whichever comes first) [Approximately 24 months]"
            }, 
            {
                "measure": "Gene mutation status of Notch activation markers as well as other genes of interest in relevant indications, in tumor, and gene expression levels of Notch activation markers, such as but not limited to Hes1, Deltex1, in tumor", 
                "safety_issue": "No", 
                "time_frame": "Baseline (study days -28 to -1)"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}